Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
symbols : PIRS save search
Pieris Pharmaceuticals Announces Respiratory and Ophthalmology Collaboration with Genentech
Published: 2021-05-25 (Crawled : 13:00) - biospace.com/
PIRS | $0.1571 -4.21% -1.86% 630K
|
Health Technology
|
| O: 21.62%
H: 68.44%
C: 67.11%
collaboration respiratory
Pieris Pharmaceuticals Provides Strategic Update and Announces Restructuring
Published: 2023-07-18 (Crawled : 13:20) - biospace.com/
PIRS | $0.1571 -4.21% -1.86% 630K
|
Health Technology
|
| O: 33.55%
H: 47.44%
C: -16.28%
update pharmaceuticals
Pieris Pharmaceuticals Receives Orphan Drug Designation for Cinrebafusp Alfa for the Treatment of Gastric Cancer
Published: 2021-06-24 (Crawled : 12:15) - biospace.com/
PIRS | $0.1571 -4.21% -1.86% 630K
|
Health Technology
|
| O: 5.65%
H: 22.19%
C: 16.84%
treatment cancer drug designation
Pieris Pharmaceuticals Reports Full-Year 2022 Financial Results and Business Updates
Published: 2023-03-29 (Crawled : 12:20) - biospace.com/
PIRS | $0.1571 -4.21% -1.86% 630K
|
Health Technology
|
| O: -25.68%
H: 17.27%
C: -3.64%
business pharmaceuticals financial results
Pieris Pharmaceuticals Announces Milestone Achievement for Boston Pharmaceuticals' Initiation of Phase 1/2 Study of BOS-342, a 4-1BB/GPC3 Immuno-Oncology Bispecific
Published: 2023-08-17 (Crawled : 13:00) - biospace.com/
PIRS | $0.1571 -4.21% -1.86% 630K
|
Health Technology
|
| O: 5.11%
H: 10.24%
C: 2.81%
bos-342 pharmaceuticals milestone study
Pieris Pharmaceuticals To Present at Jefferies Healthcare Conference
Published: 2022-06-02 (Crawled : 12:20) - biospace.com/
PIRS | $0.1571 -4.21% -1.86% 630K
|
Health Technology
|
| O: -3.87%
H: 8.62%
C: 5.17%
conference
Pieris Pharmaceuticals Reports First Quarter 2021 Financial Results and Provides Corporate Update
Published: 2021-05-17 (Crawled : 12:00) - biospace.com/
PIRS | $0.1571 -4.21% -1.86% 630K
|
Health Technology
|
| O: 1.6%
H: 6.81%
C: 0.52%
financial results results
Pieris Pharmaceuticals and Boston Pharmaceuticals Enter into an Exclusive Worldwide Product License for PRS-342, a 4-1BB/GPC3 Immuno-Oncology Bispecific
Published: 2021-04-26 (Crawled : 13:15) - biospace.com/
PIRS | $0.1571 -4.21% -1.86% 630K
|
Health Technology
|
| O: 0.0%
H: 6.8%
C: 6.14%
license gpt-3
Pieris Pharmaceuticals To Host Third Quarter 2022 Investor Call and Provide Corporate Update on November 2, 2022
Published: 2022-10-26 (Crawled : 13:00) - biospace.com/
PIRS | $0.1571 -4.21% -1.86% 630K
|
Health Technology
|
| O: -1.96%
H: 6.0%
C: 2.0%
pharmaceuticals update
Pieris Pharmaceuticals Announces $5 Million Milestone from Seagen for Initiation of Phase 1 Trial of CD228 x 4-1BB Bispecific Molecule (Mabcalin SGN-BB228 (PRS-346)
Published: 2023-01-10 (Crawled : 14:00) - biospace.com/
PIRS | $0.1571 -4.21% -1.86% 630K
|
Health Technology
|
| O: 4.69%
H: 5.97%
C: 5.22%
cd228 pharmaceuticals trial milestone
Pieris Pharmaceuticals to Present at Jefferies 2023 Healthcare Conference
Published: 2023-06-02 (Crawled : 22:00) - biospace.com/
PIRS | $0.1571 -4.21% -1.86% 630K
|
Health Technology
|
| O: 0.0%
H: 5.88%
C: 5.35%
conference pharmaceuticals
Pieris Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Corporate Update
Published: 2022-11-02 (Crawled : 12:00) - biospace.com/
PIRS | $0.1571 -4.21% -1.86% 630K
|
Health Technology
|
| O: 0.94%
H: 5.61%
C: -4.67%
pharmaceuticals financial update results
Pieris Pharmaceuticals Announces Successful Completion of Safety Review for 10 mg Dose of Phase 2a Trial of Elarekibep (PRS-060/AZD1402)
Published: 2023-05-04 (Crawled : 13:20) - biospace.com/
PIRS | $0.1571 -4.21% -1.86% 630K
|
Health Technology
|
| O: 0.7%
H: 5.53%
C: -2.97%
prs-060 review pharmaceuticals trial
Pieris Pharmaceuticals Announces AstraZeneca Discontinuation of Phase 2a Trial of Elarekibep (PRS-060/AZD1402) Due to New Non-Clinical Safety Findings From 13-week Toxicology Study
Published: 2023-06-21 (Crawled : 12:00) - biospace.com/
PIRS | $0.1571 -4.21% -1.86% 630K
|
Health Technology
|
| O: -58.66%
H: 5.38%
C: -29.51%
prs-060 pharmaceuticals trial study
Pieris Pharmaceuticals Announces Presentation of Positive Clinical Data for Cinrebafusp Alpa (PRS-343) At 2023 AACR Annual Meeting
Published: 2023-04-17 (Crawled : 13:00) - biospace.com/
PIRS | $0.1571 -4.21% -1.86% 630K
|
Health Technology
|
| O: 10.01%
H: 5.32%
C: 4.43%
prs-343 presentation positive pharmaceuticals meeting
Pieris Pharmaceuticals To Host Full-Year 2021 Investor Call and Provide Corporate Update on March 1, 2022
Published: 2022-02-23 (Crawled : 19:00) - biospace.com/
PIRS | $0.1571 -4.21% -1.86% 630K
|
Health Technology
|
| O: 1.32%
H: 5.21%
C: -1.95%
als
Connect Biopharma Hires General Counsel & Chief Compliance Officer and Appoints a New Board Member
Published: 2021-08-23 (Crawled : 00:00) - biospace.com/
PIRS | $0.1571 -4.21% -1.86% 630K
|
Health Technology
|
| O: 0.0%
H: 7.43%
C: 6.93%
GH M | $16.39 1.42% 1.46% 1.5M
|
Health Services
|
| O: 1.19%
H: 5.11%
C: 4.88%
biopharma
Pieris Pharmaceuticals Announces Presentation of Encouraging Preclinical Data for PRS-400 at ATS 2023 International Conference
Published: 2023-05-22 (Crawled : 14:00) - biospace.com/
PIRS | $0.1571 -4.21% -1.86% 630K
|
Health Technology
|
| O: 1.34%
H: 4.59%
C: 4.59%
prs-400 conference presentation international pharmaceuticals preclinical
Pieris Pharmaceuticals Reports First Quarter 2023 Financial Results and Business Updates
Published: 2023-05-10 (Crawled : 12:00) - biospace.com/
PIRS | $0.1571 -4.21% -1.86% 630K
|
Health Technology
|
| O: -1.76%
H: 4.19%
C: 2.99%
business pharmaceuticals financial results
HTG Appoints Biopharmaceutical Industry Veteran Christopher Kiritsy to its Board of Directors
Published: 2022-01-28 (Crawled : 13:30) - biospace.com/
ABT | News | $105.9 -3.03% 0.38% 11M
|
Health Technology
|
| O: 0.27%
H: 3.94%
C: 3.79%
PIRS | $0.1571 -4.21% -1.86% 630K
|
Health Technology
|
| O: 0.61%
H: 3.66%
C: 3.05%
HTGM | $0.48 -20.0% -26.08% 0
|
Health Technology
|
| O: 4.76%
H: 3.57%
C: -9.09%
biopharma
Gainers vs Losers
| 57% | 43% |
Top 10 Gainers
INVO | $1.82 139.47% 56.82% 220M
|
Health Technology
SINT | $0.0373 62.88% 37.26% 460M
|
Health Technology
WISA 4 | $9.25 51.64% 34.27% 64M
|
Electronic Technology
EDBL | News | $6.66 46.37% 32.39% 13M
|
GCTK | $0.715 36.27% 26.62% 600K
|
Manufacturing
TCON | $2.29 33.92% 26.61% 1.8M
|
Health Technology
TIRX | $0.4848 7.49% 24.58% 5.9M
|
SRFM 4 | $0.3859 -12.3% 23.84% 660K
|
n/a
KZIA | $0.3442 18.28% 23.42% 290K
|
Health Technology
VNDA | News | $5.24 29.38% 22.56% 24M
|
Health Technology
Your saved searches
Save your searches and get alerts when important news are released.